SCHEMBL5623906

SCHEMBL5623906

CCOC(=O)c1cnc(Cl)cc1Nc1ccc(F)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.49
MAP2K2 P36507 1/20 0.47
MAP2K1 Q02750 1/20 0.47
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
TSHR P16473 1/20 0.44
LMNA P02545 2/20 0.43
MAPK14 Q16539 2/20 0.43
TP53 P04637 1/20 0.42
CSF1R P07333 1/20 0.42
MAPT P10636 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPK13 O15264 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
JAK3 P52333 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497453 0.94 THRB (0.45) THRBMAP2K2MAP2K1MAPK1HTT
SCHEMBL5624190 0.91 MAP2K2 (0.50) THRBMAP2K2MAP2K1MAPK1TP53
SCHEMBL5624185 0.90 MAP2K2 (0.47) THRBMAP2K2MAP2K1MAPK1HTT
SCHEMBL5622895 0.89 MAP2K1 (0.61) MAP2K2MAP2K1SYK
SCHEMBL5623989 0.89 MAP2K1 (0.49) THRBMAP2K2MAP2K1MAPK1TP53
SCHEMBL6504254 0.86 MAP2K2 (0.44) THRBMAP2K2MAP2K1TP53MAPT
SCHEMBL6499106 0.85 MAP2K2 (0.46) MAP2K2MAP2K1MAPK1LMNATP53
SCHEMBL6505710 0.85 MAP2K1 (0.57) MAP2K2MAP2K1TP53JAK2JAK1
SCHEMBL5623815 0.84 MAP2K2 (0.42) THRBMAP2K2MAP2K1TP53MAPT
SCHEMBL6505308 0.84 MAP2K1 (0.47) THRBMAP2K2MAP2K1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7273877-B2 5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives WARNER-LAMBERT COMPANY, LLC (US) 2007-09-25 US disclosed
US-7273877-B2 5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives WARNER-LAMBERT COMPANY, LLC (US) 2007-09-25 US disclosed
US-7273877-B2 5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives WARNER-LAMBERT COMPANY, LLC (US) 2007-09-25 US disclosed
US-20050026964-A1 5-Substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives WARNER-LAMBERT COMPANY LLC 2005-02-03 US disclosed
WO-2005000818-A1 5-SUBSTITUTED-4-`(SUBSTITUTED PHENYL)!AMINO!-2-PYRIDONE DEVIATIVES FOR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026964-A1 5-Substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives CYP3A5, CYP4B1, CYP3A4 THRB 3088/4885MAP2K2 3777/4885MAP2K1 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.